Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of infectious disease
3.2.1.2 Technological advancements
3.2.1.3 Increasing popularity of rapid diagnostic tests
3.2.1.4 Rising awareness regarding early diagnosis among people
3.2.1.5 Increasing government initiatives for the diagnosis of infectious diseases
3.2.2 Industry pitfalls & challenges
3.2.2.1 Low accuracy of results
3.2.2.2 Availability of substitute products
3.2.2.3 Stringent regulatory framework
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.5.1 U.S.
3.5.2 Europe
3.6 Technological landscape
3.7 New emerging therapies
3.8 GAP analysis
3.9 Porter's analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Infectious disease testing
5.2.1 Respiratory infection testing products
5.2.2 Influenza
5.2.3 Hepatitis
5.2.4 HIV
5.2.5 Other infectious disease tests
5.3 Glucose monitoring
5.4 Cardiometabolic testing
5.5 Coagulation testing products
5.6 Pregnancy and fertility testing
5.7 Tumor/Cancer marker testing products
5.8 Urinalysis testing products
5.9 Cholesterol testing products
5.10 Hematology testing products
5.11 Drug-of-abuse (DoA) testing products
5.12 Fecal occult testing products
5.13 Other products
Chapter 6 Market Estimates and Forecast, By Purchase, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 OTC
6.3 Prescription-based tests
Chapter 7 Market Estimates and Forecast, By Technology/Platform, 2021 – 2032 ($ Mn)
7.1 Flow-through
7.2 Solid phase
7.3 Lateral flow
7.4 Agglutination assays
7.5 Other technologies
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Hospital pharmacies
8.2 Brick & mortar
8.3 E-commerce
8.4 Other distribution channels
Chapter 9 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
9.1 Diagnostic centers
9.2 Homecare settings
9.3 Hospitals & clinics
9.4 Other end users
Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Argentina
10.5.4 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Abbott Laboratories
11.2 ACON Laboratories Inc.
11.3 Alfa Scientific Designs Inc.
11.4 Artron Laboratories Inc.
11.5 Becton, Dickinson and Company
11.6 BioMerieux
11.7 Bio-Rad Laboratories
11.8 Danaher Corporation (HemoCue & Radiometer)
11.9 Hologic
11.10 McKesson Medical-Surgical, Inc.
11.11 Meridian Bioscience, Inc.
11.12 QIAGEN N.V.
11.13 Quidel Corporation
11.14 F. Hoffmann-La Roche Ltd.
11.15 Sight Diagnostics Ltd.
11.16 Trinity Biotech
